ERBB2 and triple-negative breast carcinoma: Among molecular subtypes, hormone receptor (HR) positive/ human epidermal growth factor receptor-2 (HER2) negative BCs show the highest survival probability (89%–96%), whereas triple-negative breast cancer (TNBC) has a survival probability of 73%–81% [2].